伊布利特治疗阵发性房颤的疗效及安全性

Clinical effects and safety of ibutilide in patients with paroxysmal atrial fibrillation

目的:观察新型Ⅲ类抗心律失常药物伊布利特转复心房纤颤的疗效。方法:选择32例房颤患者,随机分为两组:伊布利特组(18例),伊布利特1mg,于15min内静注,如无效30min后再给予1mg静注;胺碘酮组(14例),胺碘酮150mg,于15min内静注,如无效30min后再给予150mg静注。观察两组房颤转复情况及时间。结果:伊布利特组90min内转复房颤率明显高于胺碘酮组(77.8%比28.6%),4h内转复房颤率亦明显高于胺碘酮组(100%比71.4%),P<0.01。结论:伊布利特是一种转复房颤的快速、安全、有效的药物。

Objective： To observe effect of ibutilide, a new III antiarrhythmic drug, for atrial tlbrillatlon （AF） cardioversion. Methods： A total of 32 AF patients were randomly divided into ibutilide group （n = 18, received ibutilide 1mg intravenous within 15min, another lmg was given intravenously after 30min if it was invalid） and amiodarone group （n = 14, received amiodarone 150mg intravenous within 15min, another 150mg was given intravenously after 30min if it was invalid）. Cardioversion condition and time were observed in two groups, Results： Cardioversion rate of AF within 90min in ibutilide group was significantly higher than that of amiodarone group （77.8% vs. 28.6%）, that within 4h was also significantly higher than that of amiodarone group （100% vs. 71.4%）, P〈0.01 both. Conclusion： Ibutilide is a drug for safe and effective cardioversion of atrial fibrillation.